Inventor · disambiguated record
Stefan Klostermann
Also filed as: KLOSTERMANN STEFAN
19 granted patents·26 pending applications·49 citations·filing 2010–2025
92Inventor score
Top patents by PatentIndex Score
45 records- 0194US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 0292US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 0392US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 0492US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 0587US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 0687US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0784US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 0883US11987632B2Antibodies binding to HLA-A2/MAGE-A4HOFFMANN LA ROCHE·Filed 2020·Granted May 21, 2024·1 cites·68 claims
- 0982US9150641B2Sequence dependent aggregationKETTENBERGER HUBERT·Filed 2010·Granted Oct 6, 2015·8 cites·6 claims
- 1082US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1181US11192957B2Antibodies binding to HLA-A2/WT1HOFFMANN LA ROCHE·Filed 2018·Granted Dec 7, 2021·2 cites·38 claims
- 1281US2025129179A1Antibodies binding to hla-a2/wt1HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1379US2025051456A1Anti-hla-g antibodies and methods of use thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1476US2024383987A1Antibodies binding to hla-a2/mage-a4HOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1575US12098213B2Antibodies binding to HLA-A2/WT1HOFFMANN LA ROCHE·Filed 2021·Granted Sep 24, 2024·0 cites·40 claims
- 1675US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 1771US9766251B2Anti-human IgG1 antibodyHOFFMANN LA ROCHE·Filed 2015·Granted Sep 19, 2017·1 cites·26 claims
- 1871US2025051455A1Multispecific antibodies and use thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1968US2023068801A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2064US12157770B2Anti-HLA-G antibodies and methods of use thereofHOFFMANN LA ROCHE·Filed 2020·Granted Dec 3, 2024·0 cites·11 claims
- 2163US12378315B2Anti-rabbit CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Aug 5, 2025·0 cites·15 claims
- 2262US2021309730A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2361US2025263778A1Method for discovery of alternative antigen specific antibody variantsHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2460US2020347147A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2559US11981737B2Anti-HLA-G antibodies and use thereofHOFFMANN LA ROCHE·Filed 2019·Granted May 14, 2024·0 cites·9 claims
- 2659US2022220500A1Method for the production of an antibodyHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2759US2021070882A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2858US2020216880A1Method for discovery of alternative antigen specific antibody variantsHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2956US2021147554A1Multispecific antibodies and use thereofHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3055US2015246961A1Method for the expression of polypeptides using modified nucleic acidsHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3152US10047162B2Sequence dependent aggregationHOFFMANN LA ROCHE·Filed 2015·Granted Aug 14, 2018·0 cites·5 claims
- 3252US2014038210A1ANTI-HUMAN IgG1 ANTIBODYHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 3352US2020066372A1Method for improving antibody stabilityHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3447US9957331B2Non-cross-reactive anti IgG antibodiesESSIG ULRICH·Filed 2010·Granted May 1, 2018·0 cites·12 claims
- 3547US2017349669A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3646US11952421B2Bispecific antibodies against CD3EPSILON and ROR1BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 9, 2024·0 cites·6 claims
- 3746US10418126B2Method for improving antibody stabilityHOFFMANN LA ROCHE·Filed 2016·Granted Sep 17, 2019·0 cites·6 claims
- 3845US11680110B2Three-dimensional structure-based humanization methodHOFFMANN LA ROCHE·Filed 2018·Granted Jun 20, 2023·0 cites·2 claims
- 3945US2017174786A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4043US2017114146A1Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4141US2015315296A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 4240US2017096485A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4338US2017096495A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4438US2018282410A1Anti-cd3xrob04 bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 4533US2017306044A1Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancerENGMAB AG·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stefan Klostermann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →